Arrys Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Arrys Therapeutics General Information

Description

Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way.

Contact Information

Website
www.arrystherapeutics.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1030 Massachusetts Avenue
  • Suite 400
  • Cambridge, MA 02138
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Ikena Oncology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1030 Massachusetts Avenue
  • Suite 400
  • Cambridge, MA 02138
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrys Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Dec-2018 Completed Generating Revenue
1. Early Stage VC (Series A) 14-Dec-2017 Completed Startup
To view Arrys Therapeutics’s complete valuation and funding history, request access »

Arrys Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Arrys Therapeutics’s complete cap table history, request access »

Arrys Therapeutics Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 4

    Pending

  • Expiring in next 12 mo

Arrys Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021226162-A1 Ep4 antagonists and their use in the treatment of proliferative diseases Inactive 05-May-2020
CA-3113468-A1 Grapiprant unit dosage forms Pending 27-Sep-2018
EP-3856177-A1 Grapiprant unit dosage forms Inactive 27-Sep-2018
EP-3856177-A4 Grapiprant unit dosage forms Inactive 27-Sep-2018
US-20210353648-A1 Grapiprant unit dosage forms Inactive 27-Sep-2018 A61K31/64
To view Arrys Therapeutics’s complete patent history, request access »

Arrys Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlas Venture Venture Capital Minority
OrbiMed Growth/Expansion Minority
To view Arrys Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Arrys Therapeutics FAQs

  • When was Arrys Therapeutics founded?

    Arrys Therapeutics was founded in 2017.

  • Where is Arrys Therapeutics headquartered?

    Arrys Therapeutics is headquartered in Cambridge, MA.

  • What industry is Arrys Therapeutics in?

    Arrys Therapeutics’s primary industry is Drug Discovery.

  • Is Arrys Therapeutics a private or public company?

    Arrys Therapeutics is a Private company.

  • What is Arrys Therapeutics’s current revenue?

    The current revenue for Arrys Therapeutics is .

  • How much funding has Arrys Therapeutics raised over time?

    Arrys Therapeutics has raised $21M.

  • Who are Arrys Therapeutics’s investors?

    Atlas Venture and OrbiMed have invested in Arrys Therapeutics.

  • When was Arrys Therapeutics acquired?

    Arrys Therapeutics was acquired on 01-Dec-2018.

  • Who acquired Arrys Therapeutics?

    Arrys Therapeutics was acquired by Ikena Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process